SG Americas Securities LLC Buys New Position in Personalis, Inc. (NASDAQ:PSNL)

SG Americas Securities LLC bought a new stake in Personalis, Inc. (NASDAQ:PSNL) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,829 shares of the company’s stock, valued at approximately $63,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC bought a new position in Personalis in the 3rd quarter valued at about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares in the last quarter. International Assets Investment Management LLC grew its position in Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after buying an additional 17,082 shares in the last quarter. Quantbot Technologies LP bought a new position in Personalis in the 3rd quarter valued at about $210,000. Finally, Barclays PLC lifted its holdings in Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after acquiring an additional 20,444 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Trading Up 7.1 %

PSNL stock opened at $4.99 on Friday. Personalis, Inc. has a one year low of $1.13 and a one year high of $7.20. The firm has a market capitalization of $352.54 million, a PE ratio of -2.97 and a beta of 1.73. The firm has a 50-day moving average of $5.21 and a two-hundred day moving average of $4.91.

Analysts Set New Price Targets

PSNL has been the subject of a number of research analyst reports. HC Wainwright cut their price target on shares of Personalis from $11.00 to $8.00 and set a “buy” rating for the company in a report on Monday, January 27th. Lake Street Capital upped their price target on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.25 price target on shares of Personalis in a report on Wednesday, January 8th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.